Form 8-K

0001171843-20-006729.txt : 20200930 0001171843-20-006729.hdr.sgml : 20200930 20200930071046 ACCESSION NUMBER: 0001171843-20-006729 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20200930 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200930 DATE AS OF CHANGE: 20200930 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOCRYST PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000882796 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 621413174 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-23186 FILM NUMBER: 201210633 BUSINESS ADDRESS: STREET 1: 4505 EMPEROR BOULEVARD STREET 2: SUITE 200 CITY: DURHAM STATE: NC ZIP: 27703 BUSINESS PHONE: 919-859-1302 MAIL ADDRESS: STREET 1: 4505 EMPEROR BOULEVARD STREET 2: SUITE 200 CITY: DURHAM STATE: NC ZIP: 27703 8-K 1 f8k_093020.htm FORM 8-K Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 30, 2020

_______________________________

BioCryst Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

_______________________________

Delaware	000-23186	62-1413174
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

4505 Emperor Blvd., Suite 200

Durham, North Carolina 27703

(Address of Principal Executive Offices) (Zip Code)

(919) 859-1302

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	BCRX	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

On September 30, 2020, BioCryst Pharmaceuticals, Inc. (the "Company") issued a news release announcing new data from treatment-naïve (no prior treatment with C5 inhibitors) paroxysmal nocturnal hemoglobinuria (PNH) patients receiving doses through 400 mg bid of its oral Factor D inhibitor, BCX9930, as monotherapy in an ongoing dose-ranging trial. A copy of the news release, which also referenced a conference call and webcast to discuss the new data, is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

The information in this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description

99.1		Press release dated September 30, 2020 entitled "BioCryst's Oral Factor D Inhibitor, BCX9930, Shows Clinical Benefit as Monotherapy Through 400 mg bid in Treatment-naïve PNH Patients"
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	BioCryst Pharmaceuticals, Inc.


Date: September 30, 2020	By:	/s/ Alane Barnes
		Alane Barnes
		Senior Vice President and Chief Legal Officer

EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling

EXHIBIT 99.1

BioCryst’s Oral Factor D Inhibitor, BCX9930, Shows Clinical Benefit as Monotherapy Through 400 mg bid in Treatment-naïve PNH Patients

RESEARCH TRIANGLE PARK, N.C., Sept. 30, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced new data from treatment-naïve (no prior treatment with C5 inhibitors) paroxysmal nocturnal hemoglobinuria (PNH) patients receiving doses through 400 mg bid of its oral Factor D inhibitor, BCX9930, as monotherapy in an ongoing dose-ranging trial.

Oral BCX9930 is driving rapid and dose-dependent reductions in key biomarkers, including LDH, and increasing hemoglobin levels in all PNH patients in the trial. Increases in hemoglobin levels were maintained without transfusions.

BCX9930 has been safe and well tolerated at all doses in the trial. No drug-related serious adverse events have been reported.

“We are thrilled with the clinical benefits and safety profile of oral BCX9930 monotherapy that we continue to see in PNH patients with dosing up to 400 mg bid. With these excellent results, we plan to initiate advanced development trials next year in multiple complement-mediated hematology and nephrology diseases,” said Dr. William Sheridan, chief medical officer of BioCryst.

The FDA has granted both Fast Track status and Orphan Drug Designation to BCX9930 for PNH. BioCryst has confirmed meetings with regulators in the 4^th quarter of 2020 to discuss the advanced development program for BCX9930.

Updated Data Through 400 mg bid

All seven PNH patients in the trial were severely ill, with pre-treatment LDH from 3.8 to 11 × ULN, indicating active hemolysis. Four patients had a history of compromised bone marrow function, and two had thrombotic, lung or kidney complications from PNH.
New data from the four treatment-naïve PNH patients who have received more than six weeks of therapy at 400 mg bid show significant clinical benefits for these patients.

º Hemoglobin levels increased by a mean of 3.8 g/dL from baseline. These increases are being maintained without transfusions.

º Three of four patients have responded with hemoglobin levels >11 g/dL to date. Hemoglobin in the fourth patient, who has compromised bone marrow function from aplastic anemia PNH, responded with an increase from 6 g/dL at baseline to 9.5 g/dL on treatment.

º In all four patients, the size of the PNH red blood cell clone approached that of the PNH granulocyte clone, indicating near-complete control of complement-mediated hemolysis. The mean relative (red blood cells/granulocytes) PNH red blood cell clone size increased from 48 percent at baseline to 94 percent on treatment.

º All four patients have shown reductions in LDH. Three of four patients show average serial LDH of <1.5 × ULN. In the fourth patient, the LDH has decreased from a pretreatment baseline of 11 × ULN to 2.2 × ULN on treatment to date.

º All four patients have continued on therapy with BCX9930 based on the investigators’ assessment of clinical benefit.
The most common adverse event was mild to moderate headache lasting one to three days. One patient had a mild rash that resolved after continued BCX9930 dosing at 100 mg bid. One patient had a mild rash at 200 mg bid that is resolving during uninterrupted dosing after dose escalation to 400 mg bid.

In addition to the ongoing dose-ranging trial in treatment-naïve PNH patients, the company plans to report data from PNH patients with an inadequate response to C5 inhibitors receiving at least 400 mg bid of BCX9930 by the end of 2020.

Additional details can be found on slides, which can be accessed at the Investors’ section of BioCryst’s website at http://www.biocryst.com.

Conference Call and Webcast
BioCryst management will host a conference call and webcast at 8:30 a.m. ET today to discuss the new data. The live call may be accessed by dialing 877-303-8027 for domestic callers and 760-536-5165 for international callers and using conference ID # 6798951. A live webcast of the call and any slides will be available online at the investors section of the company website at www.biocryst.com. A telephone replay of the call will be available by dialing 855-859-2056 for domestic callers or 404-537-3406 for international callers and entering the conference ID #6798951.

About the Alternative Pathway and Complement-Mediated Diseases
The complement system is part of the body’s natural immune system and is responsible for helping the body eliminate microbes and damaged cells. Once activated, the complement system stimulates inflammation, phagocytosis and cell lysis. Excessive or uncontrolled activation of the complement system can cause severe, and potentially fatal, immune and inflammatory disorders. Patients with these diseases currently have no approved treatments or are limited to treatment with repeated intravenous infusions.

The alternative pathway is constantly active and provides a critical amplification loop for all three pathways (alternative, lectin, classical) of the complement system, regardless of the initiating mechanism. Factor D is an essential enzyme, and the first enzyme, in the alternative pathway, making Factor D an attractive target to address complement-mediated diseases.

About BCX9930
Discovered by BioCryst, BCX9930 is a novel, oral, potent and selective small molecule inhibitor of Factor D currently in Phase 1 clinical development for the treatment of complement-mediated diseases. In an ongoing dose ranging trial of BCX9930 in patients with PNH, BCX9930 was safe and well tolerated, with no drug-related serious adverse events. As a Factor D inhibitor, BCX9930 is designed as an oral monotherapy that can address both intravascular and extravascular hemolysis in PNH patients. Treatment-naïve PNH patients who have received more than six weeks of therapy at a monotherapy dose of 400 mg bid showed rapid and dose-dependent reductions in key biomarkers, including LDH, and increases in hemoglobin levels that were maintained without transfusions.

About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. BioCryst has several ongoing development programs including ORLADEYO™ (berotralstat), an oral treatment for hereditary angioedema, BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, galidesivir, a potential treatment for COVID-19, Marburg virus disease and yellow fever, and BCX9250, an ALK2 inhibitor for the treatment of fibrodysplasia ossificans progressiva. RAPIVAB^® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, is BioCryst’s first approved product and has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan, Korea and the European Union. Post-marketing commitments for RAPIVAB are ongoing. For more information, please visit the Company's website at www.BioCryst.com.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding BioCryst’s plans for its BCX9930 program. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results and developments of such program to be materially different from those expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: the ongoing COVID-19 pandemic could create challenges in all aspects of BioCryst’s business, including without limitation delays, stoppages, difficulties and increased expenses with respect to BioCryst’s and it partners’ development, regulatory processes and supply chains, negatively impact BioCryst’s ability to access the capital or credit markets to finance its operations, or have the effect of heightening many of the risks described below or in the documents BioCryst files periodically with the Securities and Exchange Commission; ongoing and future preclinical and clinical development of BCX9930 may not have positive results; BioCryst may not be able to enroll the required number of subjects in planned clinical trials of product candidates; BioCryst may not advance human clinical trials with product candidates as expected; development may be more expensive than expected; and the FDA may require additional studies beyond the studies planned for product candidates, may not provide regulatory clearances which may result in delay of planned clinical trials, may impose a clinical hold with respect to such product candidates, or may withhold market approval for product candidates. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, all of which identify important factors that could cause the actual results and developments to differ materially from those contained in BioCryst’s forward-looking statements.

BCRXW

Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com

EX-101.SCH 3 gnw-20190101.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 gnw-20190101_def.xml XBRL DEFINITION FILE EX-101.LAB 5 gnw-20190101_lab.xml XBRL LABEL FILE Class of Stock [Axis] Common Class A [Member] Preferred Class A [Member] Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 gnw-20190101_pre.xml XBRL PRESENTATION FILE XML 7 f8k_093020_htm.xml IDEA: XBRL DOCUMENT 0000882796 2020-09-30 2020-09-30 iso4217:USD shares iso4217:USD shares 0000882796 false 8-K 2020-09-30 BioCryst Pharmaceuticals, Inc. DE 000-23186 62-1413174 4505 Emperor Blvd., Suite 200 Durham NC 27703 919 859-1302 false false false false Common Stock BCRX NASDAQ false XML 8 R1.htm IDEA: XBRL DOCUMENT

Cover	Sep. 30, 2020
Document Type	8-K
Amendment Flag	false
Document Period End Date	Sep. 30, 2020
Entity File Number	000-23186
Entity Registrant Name	BioCryst Pharmaceuticals, Inc.
Entity Central Index Key	0000882796
Entity Tax Identification Number	62-1413174
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	4505 Emperor Blvd., Suite 200
Entity Address, City or Town	Durham
Entity Address, State or Province	NC
Entity Address, Postal Zip Code	27703
City Area Code	919
Local Phone Number	859-1302
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock
Trading Symbol	BCRX
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 1 95 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://globenewswire.com/role/Cover Cover Cover 1 false false All Reports Book All Reports f8k_093020.htm exh_991.htm gnw-20190101.xsd gnw-20190101_def.xml gnw-20190101_lab.xml gnw-20190101_pre.xml http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/us-gaap/2019-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "f8k_093020.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "local": [ "gnw-20190101_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "f8k_093020.htm" ] }, "labelLink": { "local": [ "gnw-20190101_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "gnw-20190101_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "gnw-20190101.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 63, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "gnw", "nsuri": "http://globenewswire.com/20190101", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "f8k_093020.htm", "contextRef": "Form8K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://globenewswire.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "f8k_093020.htm", "contextRef": "Form8K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The start date of the period covered in the document, in CCYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r9" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-US": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Common Class A [Member]" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredClassAMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Preferred Class A [Member]" } } }, "localname": "PreferredClassAMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stringItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r11": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r12": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r13": { "Name": "Forms 10-K, 20-F, 40-F", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d-1" }, "r14": { "Name": "Forms 20-F, 40-F", "Number": "249", "Publisher": "SEC", "Section": "220 and 240", "Subsection": "f" }, "r15": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r18": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" } }, "version": "2.1" } ZIP 15 0001171843-20-006729-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001171843-20-006729-xbrl.zip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